Catalyst Pharmaceuticals stock set for Nasdaq delisting
Catalyst Pharmaceuticals, Inc. has had its common stock designated for removal from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Exchange Act, through a Form 25 notification.
Rhea-AI Filing Summary
Catalyst Pharmaceuticals, Inc. has had its common stock designated for removal from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Exchange Act, through a Form 25 notification. Nasdaq states it has followed its rules to strike this class of securities, citing SEC Rule 12d2-2.
Positive
- None.
Negative
- Common stock is being removed from listing and registration on Nasdaq Stock Market LLC, which may significantly reduce on-exchange trading liquidity for Catalyst Pharmaceuticals shares.
Filing Explained
The filing documents steps to remove Catalyst Pharmaceuticals common stock from Nasdaq and withdraw its Section 12(b) registration; because it is a Form 25 notification, the supplied text does not establish that the removal is already effective.
Key Figures
Commission File Number: 001-33057
Exchange Act section: 12(b)
Headquarters ZIP code: 33134
3 metrics
Commission File Number
001-33057
SEC registration file number for Catalyst Pharmaceuticals under the Exchange Act
Exchange Act section
12(b)
Section invoked for removal of listing and registration of common stock
Headquarters ZIP code
33134
ZIP code for Catalyst Pharmaceuticals’ principal executive offices in Coral Gables, Florida
Key Terms
Form 25, Section 12(b), voluntary withdrawal, strike the class of securities from listing
4 terms
Form 25 regulatory
"Nasdaq Stock Market LLC certifies that it meets all of the requirements for filing the Form 25"
A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.
Section 12(b) regulatory
"NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT"
Section 12(b) of the U.S. Securities Exchange Act requires securities listed on a national stock exchange to be registered with the U.S. Securities and Exchange Commission (SEC) and to follow regular public reporting and disclosure rules. For investors, a 12(b) listing generally means more routine financial updates, regulatory oversight and easier buying and selling—like a storefront that must display its inventory and prices, making it simpler to inspect and trade the product.
voluntary withdrawal regulatory
"governing the voluntary withdrawal of the class of securities from listing and registration"
strike the class of securities from listing regulatory
"the Exchange has complied with its rules to strike the class of securities from listing"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Catalyst Pharmaceuticals' Form 25 mean for CPRX stock?
It records that Nasdaq has moved to remove Catalyst Pharmaceuticals’ common stock from listing and registration under Section 12(b). This changes CPRX’s status as a Nasdaq-listed security, following Nasdaq’s stated compliance with its own delisting rules.
Which securities of CPRX are affected by this Nasdaq delisting action?
The action specifically concerns Catalyst Pharmaceuticals’ common stock. Nasdaq Stock Market LLC filed a Form 25 stating it has complied with its rules to strike this entire class of securities from listing and registration on the exchange.
Which exchange is removing Catalyst Pharmaceuticals (CPRX) from listing?
The Nasdaq Stock Market LLC is the exchange involved. It certified to the SEC that it has reasonable grounds to file Form 25 and has followed its procedures to strike Catalyst Pharmaceuticals’ common stock from listing and registration.
Under what regulatory authority is CPRX being removed from Nasdaq?
The removal proceeds under Section 12(b) of the Securities Exchange Act of 1934 and related SEC Rule 12d2-2. The notice references subsections addressing exchange-initiated delisting and rules governing voluntary withdrawal of a class of securities.
Who signed the Nasdaq notification concerning Catalyst Pharmaceuticals (CPRX)?
The Form 25 notification on Catalyst Pharmaceuticals’ common stock was signed on behalf of Nasdaq Stock Market LLC by Katelin Rowe, identified in the document as a CDO Analyst and duly authorized person.
Where is Catalyst Pharmaceuticals (CPRX) headquartered according to this notice?
The company’s principal executive offices are listed as 355 Alhambra Circle, Suite 1250, Coral Gables, Florida 33134, with a telephone number of +1 305 529-2522, providing contact and location details alongside the delisting information.
AI-generated analysis. How Rhea-AI works. Not financial advice.
